Braidwell LP Buys New Position in VYNE Therapeutics Inc. $VYNE

Braidwell LP purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 916,077 shares of the company’s stock, valued at approximately $596,000. Braidwell LP owned approximately 136.73% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Two Sigma Securities LLC acquired a new stake in VYNE Therapeutics in the second quarter valued at approximately $26,000. BlackRock Inc. purchased a new position in shares of VYNE Therapeutics in the second quarter valued at $29,000. XTX Topco Ltd purchased a new position in shares of VYNE Therapeutics in the fourth quarter valued at $46,000. GSA Capital Partners LLP acquired a new stake in VYNE Therapeutics during the 2nd quarter valued at $47,000. Finally, Rangeley Capital LLC grew its holdings in VYNE Therapeutics by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after purchasing an additional 18,064 shares in the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Price Performance

VYNE Therapeutics stock opened at $28.32 on Thursday. VYNE Therapeutics Inc. has a 12-month low of $14.03 and a 12-month high of $79.75. The company has a market capitalization of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00. The firm’s fifty day moving average price is $31.49 and its 200 day moving average price is $31.48.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million.

VYNE Therapeutics Announces Dividend

The firm also recently declared a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were issued a $19.00 dividend.

VYNE Therapeutics Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.